Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Severe Acute Respiratory Syndrome × BNT162 Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

COVID-19 6 Neoplasms 2 Hematologic Neoplasms 2 Severe Acute Respiratory Syndrome 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Mastocytosis 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hypersensitivity 1 Hematopoietic and Lymphatic System Neoplasm 1 Chronic Disease 1

Interventions

proxalutamide 1 XAV-19 1 Standard of Care 1 Sodium Chloride 1 Medical Marijuana 1 BNT162 Vaccine 1 2019-nCoV Vaccine mRNA-1273 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed

746 enrolled 28 charts

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡